Lupin receives FDA approval for arthritis drug

The company gets the US health regulatory nod for arthritis drug Celebrex


The approval has been granted for celecoxib capsules in 50 mg strength

Lupin has announced that it has received approval from the United States Food and Drugs Administration (USFDA) to market generic version of GD Searle LLC's Celebrex capsules, used to treat arthritis.

The company has received final approval for its Celecoxib Capsules in 50 mg strength and also received tentative approvals for its product in strengths of 100 mg, 200 mg and 400 mg.

According to IMS sales data, Celebrex capsules had annual US sales of $2.44 billion.


Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email